Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain ; volume:14 ; number:1 ; day:12 ; month:11 ; year:2022 ; pages:1-9 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (12.11.2022), 1-9, 12.2022
- Urheber
-
Mar, Javier
Ibarrondo, Oliver
Larrañaga, Igor
Mar-Barrutia, Lorea
Soto-Gordoa, Myriam
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-022-01111-7
- URN
-
urn:nbn:de:101:1-2023012621011207652787
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mar, Javier
- Ibarrondo, Oliver
- Larrañaga, Igor
- Mar-Barrutia, Lorea
- Soto-Gordoa, Myriam
- SpringerLink (Online service)
Ähnliche Objekte (12)
Brainstem substructures and cognition in prodromal Alzheimer’s disease
EEG biomarkers in Alzheimer’s and prodromal Alzheimer’s: a comprehensive analysis of spectral and connectivity features
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease
Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
Exploration of neuroanatomical characteristics to differentiate prodromal Alzheimer’s disease from cognitively unimpaired amyloid-positive individuals
Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
Brainstem substructures and cognition in prodromal Alzheimer’s disease
EEG biomarkers in Alzheimer’s and prodromal Alzheimer’s: a comprehensive analysis of spectral and connectivity features
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease
Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
Exploration of neuroanatomical characteristics to differentiate prodromal Alzheimer’s disease from cognitively unimpaired amyloid-positive individuals
Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
Brainstem substructures and cognition in prodromal Alzheimer’s disease
EEG biomarkers in Alzheimer’s and prodromal Alzheimer’s: a comprehensive analysis of spectral and connectivity features
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease
Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
Exploration of neuroanatomical characteristics to differentiate prodromal Alzheimer’s disease from cognitively unimpaired amyloid-positive individuals